Niederer Kraft Frey advised the underwriting syndicate led by Huatai Financial Holdings on the offering of global depositary receipts (GDRs) and SIX Swiss Exchange listing of Zheijang Supcon Technology under the China-Switzerland Stock Connect. Including this transaction, NKF has now acted as Swiss issuer or underwriter counsel on ten out of the twelve GDR issuances […]
Walder Wyss advises Swiss biotech Alentis Therapeutics in connection with their USD 105m Series C funding to support the development of its lead assets. The funding round was led by Jeito Capital together with Novo
Zürcher Kantonalbank (‘ZKB’) priced its inaugural CHF 425 m Bail-in Bond issuance. ZKB’s Bail-in Bonds are novel instruments which have been designed and issued on the basis of a new legal framework allowing Cantonal
BlackSheep MadTech Fund, managed by EUREKA! Venture SGR, the first European venture capital fund with an entrepreneurial background that invests in the marketing and advertising technology industry, has been the lead investor in the USD 5
Bachem Holding successfully placed newly issued shares raising gross proceeds of approximately CHF 584 million by way of an accelerated bookbuilding to finance
Fangda Carbon New Material Co., an integrated carbon materials producer in in the People’s Republic of China with diversified product offerings, including graphite electrodes, carbon blocks, isostatic graphite and iron ore concentrates, sold 22m
The European Investment Bank (EIB) and GeNeuro, a French biopharmaceutical company, has entered through its R&D subsidiary, GeNeuro Innovation, into a financing agreement for a total amount of up to EUR 25 million. The
Roche Finance Europe issued EUR 1.25 bn Bonds guaranteed by Roche Holding on February 27, 2023. The transaction consists of a EUR 750 m tranche due August 2029 and a EUR 500 m tranche due February 2035. Banco Santander, Barclays Bank and
Sika has placed bonds in a total amount of CHF 650 million, consisting of three tranches on 6 March 2023. The payment date of the new bonds is April 13, 2023 and the new bonds will be listed on SIX
Santhera Pharmaceuticals Holding announced a private placement of shares and an amendment of its existing financing with funds managed by Highbridge Capital Management to provide up to CHF 22.2 million in aggregate, subject to certain milestones
